^
    11h
    SiMoSein: Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P=N/A, N=1000, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification + HR-positive
    |
    EndoPredict®
    17h
    Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry. (PubMed, Nat Genet)
    These findings demonstrate markedly improved PRS accuracy for BC risk prediction in African-ancestry women. Using these PRS models for screening will help promote more equitable cancer prevention efforts.
    Journal
    |
    ER (Estrogen receptor)
    |
    ER positive • ER negative
    17h
    Prognostic Significance of Different Ki-67 Cutoff Values Defined Luminal B HER2-Negative Breast Cancer. (PubMed, Cancer Invest)
    The novel findings was that luminal B (HER2-) tumors showed poor DFS regardless of Ki-67 cutoff values (14, 20 or 30%), and luminal B (HER2-) subtype(PR ≤ 20% and high Ki-67 index) tumors showed inferior OS, DMFS, and BCSS. With Ki-67 cutoff value of 20%, it was optimized to distinguish prognostic differences.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    17h
    the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer (clinicaltrials.gov)
    P2, N=94, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • MammaPrint® • EndoPredict® • Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib)
    20h
    NT-175-201: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
    P1, N=46, Recruiting, AstraZeneca | N=162 --> 46 | Trial completion date: Aug 2039 --> Jul 2029
    Enrollment change • Trial completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV • NT-175
    23h
    A Case of Invasive Ductal Carcinoma with Axillary Skip Metastasis Confined to the Interpectoral (Rotter's) Lymph Node. (PubMed, Surg Case Rep)
    This extraordinarily rare case of axillary skip metastasis limited to the interpectoral node emphasizes the potential for false-negative SN biopsies. Careful review of preoperative images, particularly MRI images, is crucial to avoid understaging. Awareness of interpectoral node involvement may help guide appropriate treatment strategies for selected patients.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    2d
    Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    MammaPrint®
    |
    paclitaxel • doxorubicin hydrochloride • Irene (pyrotinib) • cyclophosphamide • epirubicin
    3d
    Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2. (PubMed, Breast)
    Tumor histology affects the real-world effectiveness of first line ET plus CDK4/6i. In ILC, all three CDK4/6i performed similarly; therefore, treatment selection should prioritize tolerability, manageability, drug-drug interactions, and patient preferences.
    Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
    3d
    CDK4/6 Inhibitors in HER2-positive Metastatic Breast Cancer. (PubMed, Clin Breast Cancer)
    The integration of CDK4/6 inhibitors into anti-HER2 treatment strategies represents a promising approach to address the unique biology of HR + /HER2 + BC. Molecular profiling and personalized treatment strategies are essential to optimize patient outcomes and reduce unnecessary toxicity.
    Review • Journal
    |
    ER (Estrogen receptor)
    |
    HER-2 positive
    3d
    Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer. (PubMed, Cancer Treat Res Commun)
    Approximately 40 % of young women with luminal HER2-negative breast cancers have HER2-low or ultralow disease. These findings highlight the importance of accurately assessing HER2 expression in YWBC to identify candidates for emerging HER2-targeted therapies such as trastuzumab deruxtecan.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)